Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the six ratings firms that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $11.43.
A number of analysts recently commented on ATNM shares. HC Wainwright decreased their target price on Actinium Pharmaceuticals from $50.00 to $4.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Stephens initiated coverage on Actinium Pharmaceuticals in a report on Tuesday, May 14th. They set an “overweight” rating and a $25.00 price objective for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $21.00 target price on shares of Actinium Pharmaceuticals in a report on Tuesday, April 30th. Maxim Group decreased their price target on shares of Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. Finally, StockNews.com downgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th.
View Our Latest Report on Actinium Pharmaceuticals
Hedge Funds Weigh In On Actinium Pharmaceuticals
Actinium Pharmaceuticals Price Performance
Shares of ATNM stock opened at $2.05 on Friday. The company has a market cap of $61.06 million, a PE ratio of -1.20 and a beta of 0.20. Actinium Pharmaceuticals has a 52 week low of $1.33 and a 52 week high of $10.24.
Actinium Pharmaceuticals (NYSE:ATNM – Get Free Report) last posted its quarterly earnings results on Monday, August 5th. The company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.02. On average, sell-side analysts expect that Actinium Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.
Actinium Pharmaceuticals Company Profile
Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.
Featured Articles
- Five stocks we like better than Actinium Pharmaceuticals
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Why Wall Street Analysts Raised Price Targets for Suncor Stock
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Is Super Micro Computer a Buy After Shares Sink 20% on Earnings?
- Utilities Stocks Explained – How and Why to Invest in Utilities
- MarketBeat Week in Review – 8/5 – 8/9
Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.